Equities Analysts Offer Predictions for AXSM FY2027 Earnings

Axsome Therapeutics, Inc. ( NASDAQ:AXSM – Free Report ) – Equities research analysts at Leerink Partnrs lifted their FY2027 EPS estimates for Axsome Therapeutics in a research note issued to investors on Sunday, April 13th. Leerink Partnrs analyst M.

Goodman now forecasts that the company will post earnings of $4.20 per share for the year, up from their prior estimate of $4.10.



The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.79) per share. Axsome Therapeutics ( NASDAQ:AXSM – Get Free Report ) last posted its quarterly earnings results on Tuesday, February 18th.

The company reported ($0.96) EPS for the quarter, beating the consensus estimate of ($0.97) by $0.

01. The firm had revenue of $118.77 million during the quarter, compared to analysts’ expectations of $117.

83 million. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.

47%. View Our Latest Analysis on Axsome Therapeutics Axsome Therapeutics Stock Up 0.6 % Shares of AXSM opened at $104.

47 on Tuesday. Axsome Therapeutics has a 52-week low of $64.11 and a 52-week high of $139.

13. The company has a quick ratio of 2.04, a current ratio of 2.

11 and a debt-to-equity ratio of 3.22. The stock has a fifty day simple moving average of $119.

16 and a two-hundred day simple moving average of $102.20. The company has a market capitalization of $5.

09 billion, a PE ratio of -17.44 and a beta of 0.88.

Institutional Investors Weigh In On Axsome Therapeutics Several large investors have recently bought and sold shares of the stock. Pitcairn Co. boosted its stake in shares of Axsome Therapeutics by 3.

4% in the 4th quarter. Pitcairn Co. now owns 4,562 shares of the company’s stock valued at $386,000 after buying an additional 148 shares during the period.

Meridian Wealth Management LLC lifted its stake in Axsome Therapeutics by 0.7% in the fourth quarter. Meridian Wealth Management LLC now owns 21,171 shares of the company’s stock worth $1,791,000 after acquiring an additional 150 shares during the last quarter.

Summit Investment Advisors Inc. grew its holdings in Axsome Therapeutics by 4.4% during the 4th quarter.

Summit Investment Advisors Inc. now owns 3,852 shares of the company’s stock worth $326,000 after acquiring an additional 162 shares in the last quarter. Arizona State Retirement System increased its position in shares of Axsome Therapeutics by 1.

8% in the 4th quarter. Arizona State Retirement System now owns 9,054 shares of the company’s stock valued at $766,000 after purchasing an additional 164 shares during the last quarter. Finally, Intrust Bank NA raised its holdings in shares of Axsome Therapeutics by 6.

9% in the 4th quarter. Intrust Bank NA now owns 2,823 shares of the company’s stock valued at $239,000 after purchasing an additional 183 shares in the last quarter. Hedge funds and other institutional investors own 81.

49% of the company’s stock. Insiders Place Their Bets In related news, CFO Nick Pizzie sold 3,000 shares of Axsome Therapeutics stock in a transaction on Friday, February 14th. The stock was sold at an average price of $131.

07, for a total value of $393,210.00. Following the completion of the transaction, the chief financial officer now directly owns 42,187 shares in the company, valued at approximately $5,529,450.

09. This trade represents a 6.64 % decrease in their ownership of the stock.

The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink . 22.40% of the stock is owned by company insiders.

About Axsome Therapeutics ( Get Free Report ) Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. Further Reading Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.

com's FREE daily email newsletter ..